Bone cancer pain management utilizing ultrasound

• US 7,305,264 B2
• Filed: 11/22/2004
• Issued: 12/04/2007
• Est. Priority Date: 11/21/2003
• Status: Expired due to Fees

• Current Assignee: UST Incorporated
• Original Assignee: UST Incorporated
• Inventors: Chu, Yu-Chi, Larson, Eugene A., Kaminski, Perry W.
• Primary Examiner(s): Smith; Ruth S.
• Application Number:
  US10/994,421
• Publication Number:
  US 20050113872A1
• Time in Patent Office: 1,107 Days
• Field of Search: 600/427, 600/439, 600/459, 601/2, 601/3
• US Class Current: 600/427
• CPC Class Codes: A61B 6/506 for diagnosis of nerves
• CPC Class Codes: A61N 7/00 Ultrasound therapy lithotripsy A61B17/22, A61B17/225; massage using supersonic vibration A61H23/00 ; using ultrasound for introducing media into the body A61M37/0092

Abstract

Noninvasive pain treatment of skeletal cancer metastases in cancer patients utilizing planar or focused ultrasound. The ultrasound energy preferably targets at the Periosteum or immediate soft-bone-tissue interface, where local sensory pain receptors are directly affected by the growing tumor, to generate heat to destroy local sensory pain receptors so as to interrupt or block the pain feedback pathway to the central nervous system.

Claims

1. A method for reducing pain due to bone cancer, said method comprising:

targeting a region of interest with an imaging modality comprising ultrasound;

emitting therapeutic ultrasound energy from an ultrasound radiating surface and focusing the emitted therapeutic ultrasound energy on the region of interest;

producing tissue damage to nerves supplying the region of interest;

wherein imaging and therapy transducers are incorporated into a single unit whereby imaging and therapy can be accomplished with the same control interface, and

wherein the emitted ultrasound energy comprises HIFU and said focusing the emitted ultrasound causes the formation of microbubbles in the region of interest, said microbubbles producing a hyperechoic spot on said imaging modality with said hyperechoic spot being utilized in the imaging modality to monitor the progress of the nerve tissue damage.

2. The method of claim 1 wherein the ultrasound radiating surface is located external to the body and the ultrasound energy is delivered extracorporeally.

3. The method of claim 1 wherein the damage to the nerves is sub-lethal tissue and/or cellular damage, causing a temporary, reversible loss in nerve conduction.

4. The method of claim 3 wherein the sub-lethal damage the nerves is to the myelin sheath surrounding an individual axon.

5. The method of claim 3 wherein the applied acoustic intensity is delivered at a level sufficient to terminate nerve conduction, but not sufficient to irreversibly damage the surrounding tissue.

6. The method of claim 1 wherein the emitted ultrasound energy produces lethal tissue damage to predetermined nerves proximal to the region of interest.

7. The method of claim 1 wherein coupling between the HIFU transducer and a patient is accomplished with a water path, a gel couplant, or a hydrogel.

8. An apparatus for use in reducing pain due to bone cancer, said apparatus comprising:

ultrasound emitting means having an ultrasound radiating surface adapted for placement non-invasively on a patient'"'"'s skin;

said ultrasound emitting means being selectively operable to emit a selected level and/or frequency of ultrasound from said ultrasound radiating surface to a taraet site proximal to a bone cancer site;

wherein said level and/or frequency of said ultrasound is selected to produce sub-lethal or lethal nerve damage at the target site proximal to the bone cancer site and is further selected to produce a hyperechoic spot at the target site;

an imaging means for locating and displaying the bone cancer site, said imaging means monitoring the hyperechoic spot as an indicator of pain reduction progress;

wherein the ultrasound emitting means and the imaging means are incorporated into a single unit with the same control interface.

9. The apparatus of claim 8 wherein said imaging means comprises one of Computerized Axial Tomography, magnetic resonance, X-ray or ultrasound.

10. The apparatus of claim 9 wherein the imaging ultrasound comprises diagnostic ultrasound.

11. The apparatus of claim 8 wherein the nerve damage is lethal nerve damage located at the periosteum, or the immediate soft-bone-tissue interface or the myelin sheath.

12. The apparatus of claim 8 wherein the nerve damage is sub-lethal nerve damage located at the myelin sheath.

13. The apparatus of claim 8 wherein the ultrasound comprises planar or focused therapeutic ultrasound.

14. The apparatus of claim 13 wherein said ultrasound operates at a frequency range of 0.75-7.0 MHz.

15. The apparatus of claim 13 wherein said ultrasound comprises High Intensity Focused Ultrasound.